



Published in final edited form as:

Thorax. 2022 August ; 77(8): 829–833. doi:10.1136/thoraxjnl-2021-218577.

## Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis

Richard J Allen<sup>1</sup>, Amy Stockwell<sup>2</sup>, Justin M Oldham<sup>3</sup>, Beatriz Guillen-Guio<sup>1</sup>, David A Schwartz<sup>4,5,6</sup>, Toby M Maher<sup>7,8,9</sup>, Carlos Flores<sup>10,11,12</sup>, Imre Noth<sup>13</sup>, Brian L Yaspan<sup>2</sup>, R Gisli Jenkins<sup>7</sup>, Louise V Wain<sup>1,14</sup>,

International IPF Genetics Consortium

<sup>1</sup>Department of Health Sciences, University of Leicester, Leicester, UK

<sup>2</sup>Genentech, South San Francisco, USA

<sup>3</sup>Department of Internal Medicine, University of California Davis, Davis, USA

<sup>4</sup>Center for Genes, Environment and Health, National Jewish Health, Denver, USA

rja34@leicester.ac.uk .

Contribution statements

RJA, AS and BGG performed analyses. JMO, CF, IN, BLY, RGJ, LVW, HLB, WAF, IPH, SPH, MRH, NH, RBH, TMM, RJM, ABM, PLM, VN, EO, HP, GS, IS, MDT, MKBW, AA, NK, SFM, MES, YZ, TEF, DAS, MMM, MN and XS recruited individuals and performed genotyping/sequencing. LVW and RGJ supervised the study. RJA, RGJ, LVW, AS, JMO, BGG, DAS, TMM and CF, IN and BLY wrote the manuscript (all authors approved the final version).

Competing interests

L Wain reports collaborative research funding from GSK and Orion Pharma, and consultancy for Galapagos, outside of the submitted work. A Stockwell and B Yaspan are employees of Genentech/Roche and hold stock and stock options in Roche. J Oldham reports personal fees from Boehringer Ingelheim, Genentech, United Therapeutics, AmMax Bio and Lupin pharmaceuticals unrelated to the submitted work. RG Jenkins is a trustee of Action for Pulmonary Fibrosis and reports personal fees from Astra Zeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Daewoong, Galapagos, Galecto, GlaxoSmithKline, Heptares, NuMedii, PatientMPower, Pliant, Promedior, Redx, Resolution Therapeutics, Roche, Veracyte and Vicore. D Schwartz is the founder and chief scientific officer of Eleven P15, Inc., a company focused on the early detection and treatment of pulmonary fibrosis. TMM has received industry-academic funding from GlaxoSmithKline (GSK) R&D and UCB; and has received consultancy or speakers fees from Apellis, AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, GSK R&D, InterMune, ProMetic, Roche, Sanofi-Aventis, Sanumed, and UCB.

Ethics Statement

This research was conducted using previously published work with appropriate ethics approval. The PROFILE study (which provided samples for the UK and UUS studies) had institutional ethics approval at the University of Nottingham (NCT01134822 – ethics reference 10/H0402/2) and Royal Brompton and Harefield NHS Foundation Trust (NCT01110694 – ethics reference 10/H0720/12). Spanish samples were recruited under ethics approval by ethics committee from the Hospital Universitario N.S. de Candelaria (reference of the approval: PI-19/12). The UUS study also included individuals from clinical trials with ethics approval (ACE [NCT00957242] and PANTHER [NCT00650091]). UK samples were recruited across multiple sites with individual ethics approval (University of Edinburgh Research Ethics Committee [The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Study NCT04016181] 17/ES/0075, NRES Committee South West – Southmead, Yorkshire and Humber Research Ethics Committee 08/H1304/54, Nottingham Research Ethics Committee 09/H0403/59 and Royal Papworth Hospital Research Tissue Bank 18/EE/0269). For individuals recruited at the University of Chicago, consenting patients with IPF who were prospectively enrolled in the institutional review board-approved ILD registry (IRB#14163A) were included. Individuals recruited at the University of Pittsburgh Medical Centre had ethics approval from the University of Pittsburgh Human Research Protection Office (reference STUDY20030223: Genetic Polymorphisms in IPF). Individuals from the COMET (NCT01071707) and Lung Tissue Research Consortium (NCT02988388) studies were also included in the Chicago study. All subjects in the Colorado study gave written informed consent as part of IRB-approved protocols for their recruitment at each site and the GWAS study was approved by the National Jewish Health IRB and Colorado Combined Institutional Review Boards (COMIRB). Subjects in the Genentech study provided written informed consent for whole-genome sequencing of their DNA. Ethical approval was provided as per the original clinical trials (INSPIRE [NCT00075998], RIFF [NCT01872689], CAPACITY [NCT00287729 and NCT00287716] and ASCEND [NCT01366209]). For the USCF cohort, sample and data collection were approved by the University of California San Francisco Committee on Human Research and all patients provided written informed consent. For the Vanderbilt cohort, the Institutional Review Boards from Vanderbilt University approved the study and all participants provided written informed consent before enrolment.

<sup>5</sup>Department of Medicine, University of Colorado Denver, Denver, USA

<sup>6</sup>Department of Immunology, University of Colorado Denver, Denver, USA

<sup>7</sup>National Heart and Lung Institute, Imperial College London, London, UK

<sup>8</sup>Royal Brompton and Harefield Hospitals, London, UK

<sup>9</sup>Division of Pulmonary and Critical Care Medicine, University of Southern California, Los Angeles, USA

<sup>10</sup>Research Unit, Hospital Universitario Ntra. Sra. de Candelaria, Santa Cruz de Tenerife, Spain

<sup>11</sup>CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain

<sup>12</sup>Genomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Santa Cruz de Tenerife, Spain

<sup>13</sup>Division of Pulmonary & Critical Care Medicine, University of Virginia, Charlottesville, USA

<sup>14</sup>National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, Glenfield Hospital, Leicester, UK

## Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic lung condition with poor survival times. We previously published a genome-wide meta-analysis of IPF risk across three studies with independent replication of associated variants in two additional studies. To maximise power and to generate more accurate effect size estimates, we performed a genome-wide meta-analysis across all five studies included in the previous IPF risk GWAS. We utilised the distribution of effect sizes across the five studies to assess the replicability of the results and identified five robust novel genetic association signals implicating mTOR signalling, telomere maintenance and spindle assembly genes in IPF risk.

---

## Introduction

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease believed to result from an aberrant response to alveolar injury leading to a build-up of scar tissue. This progressive scarring is eventually fatal with half of individuals dying within 3 to 5 years of diagnosis<sup>1</sup>. The cause of IPF is unknown but genetics play an important role in how susceptible an individual is to IPF<sup>2</sup>.

Genome-wide association studies (GWAS) are an approach whereby genetic variants from across the genome are tested for their association with a disease. Genetic loci identified by GWAS can implicate genes important in disease pathogenesis and drugs which target the products encoded by these genetically-supported genes are twice as likely to be successful during development. The genetic association statistics from a GWAS are also widely used to identify causal markers of disease through Mendelian randomisation, to conduct heritability estimation and for genetic correlation analyses.

We recently published a GWAS of IPF risk<sup>2</sup>. The discovery GWAS consisted of three studies (named as the UK, Chicago and Colorado studies) and a replication analysis performed in two independent studies (named as the UUS [USA, UK and Spain] and Genentech studies). This analysis reported 14 genetic signals which implicated host defence, cell-cell adhesion, spindle assembly, TGF- $\beta$  signalling regulation and telomere maintenance as important biological processes involved in IPF disease risk. The effect size estimates from this analysis have been widely used in other genetic analyses<sup>3-5</sup> and have been integrated into drug target discovery pipelines.

To maximise sample sizes for detection of new genetic associations, and to generate more precise effect size estimates, we have reanalysed the data and present a meta-analysis of genome-wide data from all 5 datasets included in our previous study. The results of this analysis implicate new genetic loci in IPF pathogenesis and provide a unique resource for other studies of IPF risk and pathogenesis.

## Methods

Quality control and sample selection have been previously described<sup>2</sup>. In summary, datasets comprised of unrelated European-ancestry individuals from across the USA, UK and Spain, diagnosed using ATS/ERS guidelines<sup>6,7</sup>. Individuals in the Genentech study were sequenced using HiSeq X Ten platform (Illumina) and all other individuals were imputed from genotyping data using the HRC reference panel<sup>8</sup>. Genome-wide analyses were performed in each study separately using an additive logistic regression model adjusting for the first 10 genetic principal components to account for population stratification.

The five separate study-level GWAS were meta-analysed into one single GWAS, using an inverse-variance weighted fixed effect meta-analysis using METAL<sup>9</sup>. Variants were included in the meta-analysis if they were available in at least four studies. Genomic control was performed on the meta-analysis results using the LD score regression intercept to account for inflation not explained by polygenic effects<sup>10</sup>. Significant variants were defined as those with meta-analysis  $p < 5 \times 10^{-8}$  and conditional analyses were performed using GCTA-COJO to identify additional independent associated variants<sup>11</sup>. Independent associated variants were defined as variants remaining genome-wide significant after conditioning on the most significant variant (sentinel) in the region with consistent effect size estimates in the conditional and non-conditional analysis. Annotation of the sentinel variants was then performed using Variant Effect Predictor<sup>12</sup>.

To assess the robustness of novel results, we tested the strength and consistency of results across studies using MAMBA (Meta-Analysis Model-Based Assessment of replicability)<sup>13</sup>. Variants with a posterior probability of replicability (PPR) 90% were considered robust and likely to replicate should additional independent datasets become available.

Summary statistics (i.e. effect size estimates, standard errors, p values and basic variant information) for all variants included in the genome-wide meta-analysis can be accessed at <https://github.com/genomicsITER/PFgenetics>.

## Results

A total of 4,125 cases, 20,464 controls and 7,554,248 genetic variants were included in the analysis (Figure 1). The UUS study included one additional case (due to resolving a sample ID issue since the previous publication) and one fewer control (where the individual has since withdrawn consent from UK Biobank) than described in the previous GWAS<sup>2</sup>.

After conditional analyses, there were 23 independent signals with  $p < 5 \times 10^{-8}$  in the genome-wide meta-analysis (Figure 2). These 23 signals included all 14 associations reported in the previous GWAS (Supplementary Table 1). Of the nine novel genetic associations (Table 1), five showed evidence of replicability (PPR 90%). The sentinel variants of these five loci included variants in introns of *KNL1*, *NPRL3*, *STMN3* and *RTEL1*, and an intergenic variant in 10q25.1. All five novel variants had consistent direction of effect across all of the individual studies and reached nominal significance ( $p < 0.05$ ) in at least 3 of the studies. Twelve of the 14 previously reported signals had PPR > 90% (Supplementary Table 1).

## Discussion

By increasing the number of cases in the discovery analysis by more than 50% compared with the previous IPF risk GWAS, we identified novel genetic signals associated with IPF risk and improved the precision of estimations for previously reported signals. The five novel loci had internal evidence of replicability giving us confidence that these signals are likely to be generalisable.

The signals in *RTEL1* and *OBFC1* have been reported previously but did not meet the significance criteria of the previous three-way GWAS<sup>2</sup>. The new MAMBA analysis suggests that the consistency of effect across studies provides high confidence that the *RTEL1* signal will replicate should an independent dataset become available. This is not the case for the *OBFC1* signal where a low posterior probability of replication suggests that there may be heterogeneity in effect across the contributing studies.

The novel signals require further characterisation to determine the likely causal gene and underlying functional effect of the variants. However, some of the genes that are closest to these new signals have strong candidacy for involvement in IPF pathogenesis. *NPRL3* encodes a GATOR1 complex function component and acts through mTORC1 signalling to inhibit mTOR kinase activity<sup>14</sup>. mTOR regulates TGF- $\beta$  collagen synthesis and inhibiting mTOR leads to increased deposition of scar tissue<sup>15</sup>. We previously reported an association implicating *DEPTOR*, another mTOR inhibiting gene. We also add to the evidence that cellular ageing plays a key role in IPF pathogenesis through associations at the telomere maintenance genes *TERT*, *TERC* and *RTEL1*. We previously reported associations in spindle assembly genes (*MAD1L1* and *KIF15*) and have identified a novel genetic association in another spindle assembly gene *KNL1* (Kinetochore Scaffold 1 also known as *CASC5*). *STMN3* (Stathmin 3) implicates another cell replication process through tubulin binding<sup>14</sup>.

Our analysis also shows the benefits of including all samples in the genome-wide analysis. By utilising recent statistical methodological advances to test for the replicability of signals

when all available datasets are included in the discovery GWAS<sup>13</sup>, we were able to identify five additional variants with evidence of being robustly associated with IPF risk. Additional independent replication of these signals would strengthen the evidence for their role in IPF susceptibility.

By maximising the statistical power of the analysis, we identified novel genetic associations with IPF risk. These signals may implicate biologically relevant genes that support the importance of TGF- $\beta$  signalling and cell replication as important processes in disease pathogenesis

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Funding


R Allen is an Action for Pulmonary Fibrosis Mike Bray Research Fellow. L Wain holds a GSK/Asthma + Lung UK Chair in Respiratory Research (C17-1). This work was supported by Medical Research Council Programme grant number MR/V00235X/1. This work was supported by National Institute of Health/National Heart, Lung and Blood Institute grant numbers R56HL158935 and K23HL138190 (J Oldham). This work was supported by Wellcome Trust grant number 221680/Z/20/Z (B Guillen-Guio). For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The research was partially supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre; the views expressed are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health. The UK and UUS studies selected controls from UK Biobank under application 8389. This research used the SPECTRE High Performance Computing Facility at the University of Leicester.

## References

1. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. *N Engl J Med* 2018;378(19):1811–23. [PubMed: 29742380]
2. Allen RJ, Guillen-Guio B, Oldham JM, Ma S, Dressen A, Paynton ML, Kraven LM, Obeidat M, Li X, Ng M. Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine* 2020;201(5):564–74. [PubMed: 31710517]
3. Zhang Y, Zhao M, Guo P, Wang Y, Liu L, Zhao J, Gao L, Yuan Z, Xue F, Zhao J. Mendelian randomisation highlights hypothyroidism as a causal determinant of idiopathic pulmonary fibrosis. *EBioMedicine* 2021;73:103669. [PubMed: 34749302]
4. Wang L, Balmat TJ, Antonia AL, Constantine FJ, Henao R, Burke TW, Ingham A, McClain MT, Tsalik EL, Ko ER. An atlas connecting shared genetic architecture of human diseases and molecular phenotypes provides insight into COVID-19 susceptibility. *Genome Medicine* 2021;13(1):1–19. [PubMed: 33397400]
5. Duckworth A, Gibbons MA, Allen RJ, Almond H, Beaumont RN, Wood AR, Lunnon K, Lindsay MA, Wain LV, Tyrrell J. Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: A mendelian randomisation study. *The Lancet Respiratory Medicine* 2021;9(3):285–94. [PubMed: 33197388]
6. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier J, Flaherty KR, Lasky JA. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. *American Journal of Respiratory and Critical Care Medicine* 2011;183(6):788–824. [PubMed: 21471066]
7. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F. Diagnosis of idiopathic pulmonary fibrosis. an official ATS/ERS/JRS/ALAT clinical


practice guideline. *American Journal of Respiratory and Critical Care Medicine* 2018;198(5):e44–68. [PubMed: 30168753]

8. McCarthy S, Das S, Kretzschmar W, Durbin R, Abecasis G, Marchini J. A reference panel of 64,976 haplotypes for genotype imputation. *bioRxiv* 2016:035170.
9. Willer CJ, Li Y, Abecasis GR. METAL: Fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 2010;26(17):2190–1. [PubMed: 20616382]
10. Bulik-Sullivan BK, Loh P, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ, Price AL, Neale BM, Schizophrenia Working Group of the Psychiatric Genomics Consortium. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* 2015;47(3):291–5. [PubMed: 25642630]
11. Yang J, Ferreira T, Morris AP, Medland SE, Genetic Investigation of ANthropometric Traits (GIANT) Consortium, DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, Madden PA, Heath AC, Martin NG, Montgomery GW, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat Genet* 2012 Mar 18;44(4):369–3. [PubMed: 22426310]
12. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, Flicek P, Cunningham F. The ensembl variant effect predictor. *Genome Biol* 2016;17(1):122. [PubMed: 27268795]
13. McGuire D, Jiang Y, Liu M, Weissenkampen JD, Eckert S, Yang L, Chen F, Berg A, Vrieze S, Jiang B. Model-based assessment of replicability for genome-wide association meta-analysis. *Nature Communications* 2021;12(1):1–14
14. Stelzer G, Rosen R, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, Iny Stein T, Nudel R, Lieder I, Mazor Y, et al. GeneCards – the human gene database. The GeneCards suite: From gene data mining to disease genome sequence analysis. *Current Protocols in Bioinformatics* 2016(54):1.30.1,1.30.33. [PubMed: 27322403]
15. Woodcock HV, Eley JD, Guillotin D, Platé M, Nanthakumar CB, Martufi M, Peace S, Joberty G, Poeckel D, Good RB. The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis. *Nature Communications* 2019;10(1):6.



**Figure 1.**  
Study design and sample sizes.





**Figure 2.** Manhattan plot. Each point shows a genetic variant with chromosomal position on the x axis and the  $-\log_{10}(p)$  value on the y axis. The grey dashed line shows the genome-wide significance level ( $p=5 \times 10^{-8}$ ). Each signal is labelled with the gene implicated by that signal. Genes in grey are the novel loci that do show evidence of replicability. The plot has been truncated at  $p=10^{-30}$



**Table 1:**

Sentinel variants of novel associations.

| Chr   | Position  | rsid                     | Annotation                         | Ref allele | Effect allele | EAf   | Direction | Study p 0.05 | OR [95% CI]       | p                      | PPR          |
|---|-----------|--------------------------|------------------------------------|------------|---------------|-------|-----------|--------------|-------------------|------------------------|--------------|
| <b>i) Novel variants with high posterior probability of replication (PPR 90%)</b> |           |                          |                                    |            |               |       |           |              |                   |                        |              |
| 10  | 111229861 | rs79684490               | Intergenic (10q25.1)               | G          | A             | 4.6%  | +++++     | YYNYY        | 1.40 [1.24, 1.57] | 3.52×10 <sup>-8</sup>  | <b>94.0%</b> |
| 15  | 40931708  | rs12912339 <sup>a</sup>  | Intron of <i>KNL1</i>              | G          | A             | 15.9% | +++++     | YYNYY        | 1.30 [1.21, 1.39] | 7.41×10 <sup>-13</sup> | <b>96.5%</b> |
| 16  | 162240    | rs74614704               | Intron of <i>NPRL3</i>             | G          | A             | 5.6%  | +++++     | YNNYY        | 1.49 [1.33, 1.67] | 2.57×10 <sup>-12</sup> | <b>99.4%</b> |
| 20  | 62284170  | rs112087793 <sup>b</sup> | Intron of <i>STMN3</i>             | T          | C             | 91.5% | +++++     | YYYYY        | 1.34 [1.21, 1.48] | 1.09×10 <sup>-8</sup>  | <b>96.8%</b> |
| 20  | 62324391  | rs41308092 <sup>b</sup>  | Intron of <i>RTEL1</i>             | G          | A             | 2.1%  | +++++     | YYYYN        | 1.75 [1.45, 2.10] | 3.13×10 <sup>-9</sup>  | <b>99.9%</b> |
| <b>ii) Novel variants not reaching PPR 90% threshold</b>                          |           |                          |                                    |            |               |       |           |              |                   |                        |              |
| 1   | 214659598 | rs4233306                | Intron of <i>PTPN14</i>            | T          | C             | 80.2% | +++++     | YYNNN        | 1.23 [1.15, 1.32] | 3.41×10 <sup>-9</sup>  | 37.4%        |
| 6   | 43352980  | rs1214759                | Intergenic (6p21.2)                | A          | G             | 67.9% | +++++     | NYYYY        | 1.18 [1.11, 1.25] | 1.71×10 <sup>-8</sup>  | 21.9%        |
| 9   | 109480268 | rs11788059               | Regulatory region variant (9q31.2) | T          | C             | 34.2% | +++++     | NYNYY        | 1.17 [1.10, 1.23] | 4.85×10 <sup>-8</sup>  | 3.1%         |
| 10  | 105640978 | rs7100920                | Regulatory region of <i>OBFC1</i>  | C          | T             | 49.0% | ++-++     | NYNYY        | 1.19 [1.13, 1.26] | 1.67×10 <sup>-10</sup> | 32.1%        |

Novel variants are defined as those not reaching significance criteria in previous analysis<sup>2</sup> (the *RTEL1* and *OBFC1* signals have previously shown a possible association – see discussion). Effect sizes and directions are given in terms of the allele that increases risk of IPF. Chr=Chromosome.

Position is based on genetic build 37. Annotation obtained from Variant Effect Predictor<sup>12</sup>. EAF=Effect allele frequency calculated across the five studies. The “Direction” column shows the direction of the beta in each of the five individual studies (+ means beta>0, – means beta<0). The “Study p 0.05” column denotes which individual studies the variant reached nominal significance in (Y means p 0.05, N means p>0.05). Both the direction and study p<0.05 are given in the order UK, Colorado, Chicago, UUS and then Genentech. OR=Odds ratio. CI=Confidence interval. PPR=posterior probability of replicability calculated using MAMBA<sup>13</sup>.

<sup>a</sup>The signal at *KNL1* is independent of the previously reported nearby signal in the *IVD* gene.

<sup>b</sup>The *RTEL1* and *STMN3* signals are independent of each other.